嗜酸性食管炎
医学
食品药品监督管理局
嗜酸性胃肠炎
食物过敏
嗜酸性
疾病
胃肠道疾病
皮肤病科
过敏
重症监护医学
内科学
病理
免疫学
环境卫生
作者
Marc E. Rothenberg,S Hottinger,Nirmala Gonsalves,Glenn T. Furuta,Margaret H. Collins,AC Nicholas J. Talley,Kathryn A. Peterson,Calies Menard‐Katcher,Macie Smith,Ikuo Hirano,Robert M. Genta,Mirna Chehade,Sandeep K. Gupta,Jonathan M. Spergel,Seema S. Aceves,Evan S. Dellon
标识
DOI:10.1016/j.jaci.2021.12.768
摘要
The US Food and Drug Administration hosted a workshop on July 21, 2021, to discuss the disease characteristics, natural history, and end points to assess treatment benefit in patients with eosinophilic gastrointestinal disorders (EGIDs) beyond eosinophilic esophagitis (EoE). Notably, EGIDs beyond EoE, such as eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis, herein referred to as non-EoE EGIDs, are understudied relative to EoE. This workshop provided a forum for open discussion among stakeholders-medical professionals (including their societies and research groups), Food and Drug Administration representatives, an industry representative, and a patient representative-to facilitate drug development. Experts in many disciplines related to EGIDs, including allergy, immunology, epidemiology, gastroenterology, and pathology, and both adult and pediatric clinicians contributed. Herein, we discuss some of the insights of the material presented at the meeting and present perspectives on moving the field forward toward drug approval.
科研通智能强力驱动
Strongly Powered by AbleSci AI